Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2007

View Archived Issues

Potent antiarthritic activity of the MetAP2 inhibitor PPI-2458 shown in a rat RA model

KV to acquire U.S. marketing rights to EvaMist

Rhophylac approved for ITP

IND submission for phase Ia study of intravenous Tbeta4 for cardiovascular disease

Milestone in Ranbaxy's collaboration with GSK

Vivitrol filed for approval in U.K. and Germany

Second pivotal trial begins for naproxcinod

BTG updates pipeline progress of last year

Beyond Advair compounds show similar bronchodilator activity to salmeterol

ACUITY trial shows efficacy at 1 year of bivalirudin in acute coronary syndromes

Snapshots: Recent studies of antibacterial agents

BOL-303224-A: a novel fluoroquinolone with potential utility in bacterial conjunctivitis

Lilly's dual endothelial and hepatic lipase inhibitors modulate HDL cholesterol levels in vivo

New Nav1.7 channel blocker described by Merck

Recent patent reports novel therapeutic agents for thrombotic disorders

Novel agents for treating respiratory and allergic disorders disclosed in recent patents

Recent patents describe new antidiabetic agents

CSL submits BLA for influenza vaccine

Apricitabine shows broader range of activity against drug-resistant HIV strains

New phase I trial evaluates s.c. Belerofon

SPA for new phase III trial of Prestara

Pharmexa and Affitech enter diabody license agreement

Phase III registration studies of Vectibix not affected by PACCE discontinuation

Start of pivotal trial for Pollinex Quattro ragweed

ChemGenex raises funds to support Ceflatonin development program

NB-002 studied in phase II trial for onychomycosis

Pharmacyclics' NDA for Xcytrin to be filed over protest

Supplemental BLA for Campath for first-line treatment of B-CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...